Long-term extension study of odevixibat for biliary atresia
Part of Digestive system, Genetic & congenital clinical trials.
This study follows children with biliary atresia who finished an earlier 104-week treatment study, to check how well odevixibat works over the long term and whether it remains safe. If you completed the prior study, this extension may be an option to continue monitoring and treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You finished the earlier 104-week odevixibat study (Study A4250-011).
- A caregiver can sign informed consent to join this long-term follow-up.
- Your previous participation was considered compliant with study dosing and study procedures.
- You do not have a known allergy (hypersensitivity) to odevixibat or its ingredients.
- You are not planning a liver transplant in the near future, based on the study doctor’s judgment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study enrolls children and young adults with biliary atresia (a condition where bile can’t flow properly from the liver) to learn from their care and outcomes over scheduled visits. It may help researchers understand the disease better and improve future treatment.
This study tracks the safety of odevixibat (a liver medicine) in women who took it during pregnancy or while breastfeeding. It helps patients and doctors understand if the medicine poses any risks.
This study follows people with Alagille syndrome who are already taking or starting odevixibat (Bylvay). It looks at how well the medicine works and how safe it is over a long period of time.
This study follows patients with PFIC (a rare liver disease affecting bile flow) who are taking or planning to take odevixibat (Bylvay), a medication that helps manage the condition. Researchers will track how well the medication works, any side effects, and long-term health outcomes in Chinese patients.
This study follows patients with Alagille syndrome who are taking odevixibat to see how safe the medicine is over time. Alagille syndrome is a rare liver disease that affects bile flow, and odevixibat is a treatment that may help reduce itching and improve liver function.
This study is tracking how well odevixibat (Bylvay) works and how safe it is for people with progressive familial intrahepatic cholestasis (PFIC) in South Korea. It is for patients who are already prescribed this medicine by their doctor, and it monitors their progress over time.
Hear when a new Biliary Atresia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.